Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Role of gemcitabine in ovarian cancer treatment Lorusso D; Di Stefano A; Fanfani F; Scambia GAnn Oncol 2006[May]; 17 Suppl 5 (ä): v188-94Newer agents and combinations are needed in order to improve current results in ovarian cancer treatment. Gemcitabine is a novel agent that has shown promising activity as a single agent in the treatment of platinum-resistant ovarian cancer and a favorable toxicity profile. Because of its clinical and preclinical synergism with platinum analogues, Gemcitabine has been combined with Carboplatin as a convincing approach in the treatment of platinum-sensitive recurrent ovarian cancer patients. Further combination of Gemcitabine and other agents, including paclitaxel, are also feasible and have been actively studied in order to establish the role of Gemcitabine in the management of treated and untreated ovarian cancer patients.|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|Carcinoma/*drug therapy/mortality/pathology[MESH]|Deoxycytidine/administration & dosage/*analogs & derivatives/pharmacology[MESH]|Drug Resistance, Neoplasm/drug effects[MESH]|Female[MESH]|Gemcitabine[MESH]|Humans[MESH]|Neoadjuvant Therapy[MESH]|Neoplasm Recurrence, Local[MESH]|Ovarian Neoplasms/*drug therapy/mortality/pathology[MESH]|Platinum Compounds/administration & dosage[MESH]|Survival Analysis[MESH]|Treatment Outcome[MESH] |